心房颤动中P-糖蛋白影响药物的处方频率。 - Suppr

Suppr

超能文献

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation.

作者信息

Jungbauer L, Dobias C, Stöllberger C, Weidinger F

出版信息

J Thromb Haemost. 2010 Sep;8(9):2069-70. doi: 10.1111/j.1538-7836.2010.03943.x.

DOI:10.1111/j.1538-7836.2010.03943.x

PMID:20553377

Abstract

摘要

相似文献

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation.

J Thromb Haemost. 2010 Sep;8(9):2069-70. doi: 10.1111/j.1538-7836.2010.03943.x.

Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled.

Eur J Intern Med. 2016 May;30:e17-e18. doi: 10.1016/j.ejim.2016.01.016. Epub 2016 Jan 28.

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.

Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073. Epub 2016 Jun 21.

Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.

Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):937-48. doi: 10.1517/17425255.2015.1027683. Epub 2015 Mar 22.

Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.

J Thromb Haemost. 2011 Mar;9(3):441-9. doi: 10.1111/j.1538-7836.2010.04179.x.

Starting anticoagulation with vitamin k antagonists alone or with concomitant low-molecular weight heparin for non-valvular atrial fibrillation.

Eur J Intern Med. 2019 Jan;59:e14-e15. doi: 10.1016/j.ejim.2018.09.016. Epub 2018 Sep 28.

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.

BMC Cardiovasc Disord. 2021 Oct 13;21(1):493. doi: 10.1186/s12872-021-02295-w.

Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study.

J Thromb Haemost. 2014 Sep;12(9):1413-8. doi: 10.1111/jth.12662. Epub 2014 Aug 11.

Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France.

Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):32-8. doi: 10.1002/pds.1329.

Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.

BMC Cardiovasc Disord. 2016 May 10;16:84. doi: 10.1186/s12872-016-0269-4.

引用本文的文献

Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.

Thromb J. 2018 Nov 12;16:28. doi: 10.1186/s12959-018-0183-3. eCollection 2018.

Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.

Sci Rep. 2018 Jul 12;8(1):10514. doi: 10.1038/s41598-018-28622-4.

In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.

Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):183-191. doi: 10.1007/s13318-017-0434-x.

Perioperative management of patients on direct oral anticoagulants.

Thromb J. 2017 May 15;15:14. doi: 10.1186/s12959-017-0137-1. eCollection 2017.

Rivaroxaban-Induced Hemorrhage Associated with Genetic Defect.

Front Pharmacol. 2016 Dec 19;7:494. doi: 10.3389/fphar.2016.00494. eCollection 2016.

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.

Crit Care. 2015 Apr 29;19(1):203. doi: 10.1186/s13054-015-0930-9.

Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.

Herz. 2015 Apr;40 Suppl 2:140-5. doi: 10.1007/s00059-014-4188-9. Epub 2015 Jan 25.

Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.

Pharmaceuticals (Basel). 2012 Feb 3;5(2):155-68. doi: 10.3390/ph5020155.

Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Drugs Aging. 2013 Sep;30(9):687-99. doi: 10.1007/s40266-013-0101-0.

Dabigatran and kidney disease: a bad combination.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1591-7. doi: 10.2215/CJN.01260213. Epub 2013 Jul 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验